Increasing prevalence of cancer across the globe is anticipated to fuel the growth of the global tumor ablation market at a CAGR of 11.81% during the forecast period of 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Tumor Ablation Market” that contains the information from 2018 to 2030.

The tumor ablation market is expected to register a CAGR of 11.81% during the forecast period 2023-2032, to reach USD 3.67 billion by 2032.

MRFR recognizes the following companies as the key players in the global tumor ablation market— SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany).

Market Highlights

The global tumor ablation market is expected to have a market value of USD 2,459.74 million by 2030.

Tumor ablation is a treatment that destroys liver tumors by the use of a needle. These techniques can be used in small tumors and surgery is not possible in the patient. Ablation is an effective technique for tumors no longer than 3 cm across as well as slightly larger tumors such as 1 to 2 inches, or 3 to 5 cm across, it can be used along with embolization. Because ablation can be destroyed normal tissue around the tumor. The growth of tumor ablation is driven by the rising demand for minimally invasive tumor ablation techniques. However, side effect and complications associated with tumor ablation is likely to restrain the market growth.     

Segment Analysis

The global tumor ablation market is segmented into technology, treatment, application, end-user, and region. The technology segment is further segmented into radiofrequency, microwave, irreversible electroporation, cryoablation, others. The treatment segment is further sub-segmented into surgical ablation, percutaneous ablation, laparoscopic ablation. The application segment is further sub-segmented into liver cancer, lung cancer, kidney cancer, and others. The end-user segment is further sub-segmented into hospitals and clinics, specialty centers, others.

Regional Analysis

The global tumor ablation market, based on region, has been divided into North America, Europe, Asia-Pacific, Rest of the World.

North America accounted for the largest market share of about 40.29% in 2020, owing to the advances in percutaneous ablation, growing demand for radiofrequency ablation for hepatocellular carcinoma, increasing geriatric population, and growing tumor-related issues among the population aged 65 years and above. According to the National Cancer Institute, in 2020, the US constitutes 1,806,590 new cases of cancer, and the country also recorded a total death of 606,520 cancer patients. However, the advancement in tumor treating techniques has increased the ratio of cancer survivors. According to the American Cancer Society, Inc., the total number of US. -based male cancer survivors in 2019 was 8,138,790, whereas the number of US-based female cancer survivors was accounted to be 8,781,580. In addition, the organization had also estimated the number of male and female cancer survivors to rise by 2030.

Europe is the second-largest market for tumor ablation due to the emergence of standardized methods and tools for tumor ablation treatment, growing demand for surgery radiotherapy and chemotherapy for early detected tumors, and increasing cases of various cancer among mid-aged and geriatric population and rising consumption of unhealthy and carcinogenic products. In addition, the government authorities have introduced early detection guidelines, screening programs, and vaccination coverage to increase the survival rate of the patients. Among the different types of cancers, lung cancer has the highest mortality rate, followed by colorectal cancer. Other factors that support the increasing demand for tumor ablation treatment include infections, obesity, occupational risk, and high exposure to UV. Moreover, according to WHO, Europe contributes about one-quarter of global cancer patients with 3.7 million new patients per year.

Asia-Pacific is expected to grow significantly in the tumor ablation market owing to the increasing consumption of carcinogenic products such as alcohol and betel nut, limited intake of fruits and vegetables, a revelation to indoor and outdoor air pollution, and rise in exposure to chemical pollutants across the region. Countries such as China are practicing microwave technology to treat lung tumors. Patients across the region suffering from non-small cell lung cancer (NSCLC) are being treated using microwave ablation technology.

The Rest of the World is expected to witness a rise in tumor ablation treatment. The increasing use of tobacco products and the high prevalence of smoking across the Middle East and North Africa (MENA) region activate oncogenes, further developing different types of tumors. Increasing tests for tumor molecular characterization of lung cancer across the region is expected to drive the tumor ablation market. The rising number of hepatic tumors among the Rest of the World population is generating opportunities for the industry players. Moreover, the healthcare centers in Latin America are practicing different techniques to treat patients suffering from various tumors. In addition, the high consumption of tobacco-based products across the territory is the major reason for tumor formation.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Tumor Ablation Market Research Report

Key Findings of the Study

• The global tumor ablation market is estimated to reach USD 2,459.74 million by 2030 at a CAGR of 11.81% during the assessment period.


• North America accounted for the largest share of the global tumor ablation market due to the advances in percutaneous ablation, growing demand for radiofrequency ablation for hepatocellular carcinoma, increasing geriatric population, and growing tumor-related issues among the population aged 65 years and above. According to the National Cancer Institute, in 2020, the US constitutes 1,806,590 new cases of cancer, and the country also recorded a total death of 606,520 cancer patients. However, the advancement in tumor treating techniques has increased the ratio of cancer survivors. According to the American Cancer Society, Inc., the total number of US-based male cancer survivors in 2019 was 8,138,790, whereas the number of US-based female cancer survivors was accounted to be 8,781,580.


• Based on technology, the radiofrequency segment accounted for the largest market share of 48.96% in 2020.


• Based on treatment, the surgical ablation segment accounted for the largest market share of 52.99% in 2020.


• Based on application, the lung cancer segment accounted for the largest market share of 25.80% in 2020.


• Based on end user, the hospital and clinics segment accounted for the largest market share of 55.08% in 2020.


• Some of the key players operating in the tumor ablation market are SonaCare Medical, LLC (US), Medtronic plc (Ireland), EDAP TMS (France), Angio Dynamics (US), HealthTronics, Inc (US), Johnson & Johnson (US), Boston Scientific Corporation (US), Misonix Inc (US), HistoSonics, Inc (US), Biotronik (Germany).